Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares. This sentiment was posted as part of the firm’s broader research note that previewed 2026 for MedTech. Truist expressed a more positive outlook on the healthcare sector for 2026 due to increasingly attractive relative valuations. However, the firm cautioned that the sector might act as a source of funds rather ...